Open AccessEfficacy of lopinavir–ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: a meta-analysis
Author(s) -
Jiawen Deng,
Fangwen Zhou,
Wenteng Hou,
Kiyan Heybati,
Saif Ali,
Oswin Chang,
Zachary Silver,
Thanansayan Dhivagaran,
Harikrishnaa Ba Ramaraju,
Chi Yi Wong,
Qi Zuo,
Elizabeth Lapshina,
Madeline Mellett
Publication year - 2022
Publication title -
future virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.462
H-Index - 34
eISSN - 1746-0808
pISSN - 1746-0794
DOI - 10.2217/fvl-2021-0066
Subject(s) - lopinavir , medicine , lopinavir/ritonavir , meta analysis , ritonavir , adverse effect , incidence (geometry) , covid-19 , odds ratio , observational study , randomized controlled trial , mechanical ventilation , viral load , virology , human immunodeficiency virus (hiv) , antiretroviral therapy , physics , disease , infectious disease (medical specialty) , optics
Aim: To evaluate the efficacy and safety of lopinavir-ritonavir (LPV/r) therapy in treating hospitalized COVID-19 patients. Materials & methods: Data from randomized and observational studies were included in meta-analyses. Primary outcomes were length of stay, time for SARS-CoV-2 test conversion, mortality, incidence of mechanical ventilation, time to body temperature normalization and incidence of adverse events. Results: Twenty-four studies (n = 10,718) were included. LPV/r demonstrated no significant benefit over the control groups in all efficacy outcomes. The use of LPV/r was associated with a significant increase in the odds of adverse events. Conclusion: Given the lack of efficacy and increased incidence of adverse events, the clinical use of LPV/r in hospitalized COVID-19 patients is not recommended.